KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other Accumulated Expenses (2019 - 2023)

GoodRx Holdings' Other Accumulated Expenses history spans 5 years, with the latest figure at $8.5 million for Q1 2023.

  • For Q1 2023, Other Accumulated Expenses rose 77.36% year-over-year to $8.5 million; the TTM value through Mar 2023 reached $8.5 million, up 77.36%, while the annual FY2022 figure was $6.9 million, 58.98% up from the prior year.
  • Other Accumulated Expenses for Q1 2023 was $8.5 million at GoodRx Holdings, up from $6.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $11.4 million in Q3 2022 and bottomed at $1.9 million in Q4 2019.
  • The 5-year median for Other Accumulated Expenses is $5.2 million (2021), against an average of $5.9 million.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 278.91% in 2020 before it crashed 39.64% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.9 million in 2019, then surged by 278.91% to $7.2 million in 2020, then plummeted by 39.64% to $4.3 million in 2021, then soared by 58.98% to $6.9 million in 2022, then rose by 23.44% to $8.5 million in 2023.
  • Per Business Quant, the three most recent readings for GDRX's Other Accumulated Expenses are $8.5 million (Q1 2023), $6.9 million (Q4 2022), and $11.4 million (Q3 2022).